{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:11:07Z","timestamp":1780089067583,"version":"3.54.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2303100"],"award-info":[{"award-number":["2022YFC2303100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3043514"],"award-info":[{"award-number":["2023YFC3043514"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.isci.2025.111907","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:10:20Z","timestamp":1738005020000},"page":"111907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes"],"prefix":"10.1016","volume":"28","author":[{"given":"Guanyue","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guotao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zujiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-3444","authenticated-orcid":false,"given":"Zhigang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.111907_bib1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2025.111907_bib2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1126\/science.abm4915","article-title":"The changing epidemiology of SARS-CoV-2","volume":"375","author":"Koelle","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.111907_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12979-020-00192-y","article-title":"SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done?","volume":"17","author":"Mazucanti","year":"2020","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.isci.2025.111907_bib4","doi-asserted-by":"crossref","first-page":"m1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20 133\u00a0UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2025.111907_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40200-021-00779-2","article-title":"Diabetes prevalence and mortality in COVID-19 patients: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Saha","year":"2021","journal-title":"J.\u00a0Diabetes Metab. Disord."},{"key":"10.1016\/j.isci.2025.111907_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.dsx.2020.04.044","article-title":"Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis","volume":"14","author":"Kumar","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.isci.2025.111907_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-052422-020316","article-title":"Treatments for COVID-19","volume":"75","author":"Andrews","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.isci.2025.111907_bib9","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.111907_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2025.111907_bib11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(23)00011-7","article-title":"Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study","volume":"23","author":"Aggarwal","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2025.111907_bib12","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1093\/cid\/ciac600","volume":"76","author":"Li","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2025.111907_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14393","article-title":"Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong","volume":"6","author":"Lui","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.isci.2025.111907_bib14","first-page":"236","article-title":"Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal. Transduct","volume":"5","author":"Yu","year":"2020","journal-title":"Target Ther"},{"key":"10.1016\/j.isci.2025.111907_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1215916","article-title":"Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients","volume":"10","author":"de Souza","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.isci.2025.111907_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202001435","article-title":"A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study","volume":"7","author":"Ren","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.isci.2025.111907_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101981","article-title":"Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study","volume":"59","author":"Sun","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.isci.2025.111907_bib18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2025.111907_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12879-023-08828-2","article-title":"Azvudine versus nirmatrelvir-ritonavir for oral treatment of COVID-19 in Chinese patients","volume":"24","author":"Su","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.isci.2025.111907_bib20","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.jinf.2023.05.012","article-title":"Azvudine versus Nirmatrelvir-ritonavir for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities","volume":"87","author":"Dian","year":"2023","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.isci.2025.111907_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28756","article-title":"Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study","volume":"95","author":"Deng","year":"2023","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.isci.2025.111907_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2025.111907_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274294","article-title":"Head-to-head comparison of azvudine and nirmatrelvir\/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2025.111907_bib24","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/j.jinf.2023.03.023","article-title":"Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19","volume":"86","author":"Gao","year":"2023","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.isci.2025.111907_bib25","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin","volume":"21","author":"Dalva-Aydemir","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225001671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225001671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:59:29Z","timestamp":1780088369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225001671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2589004225001671"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.111907","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.111907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111907"}}